

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 October 2022 (13.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/216723 A9

(51) International Patent Classification:
C07K 16/30 (2006.01)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:
PCT/US2022/023501

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:
05 April 2022 (05.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/170,917 05 April 2021 (05.04.2021) US

(71) Applicant: CYTOVIA THERAPEUTICS, LLC.
[US/US]; 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(72) Inventors: KADOUCHE, Jean; c/o Cytovia Therapeutics, Inc., 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US). LI, Wei; c/o Cytovia Therapeutics, Inc., 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US). TEPER, Daniel; c/o Cytovia Therapeutics, Inc., 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).

(48) Date of publication of this corrected version:

31 August 2023 (31.08.2023)

(74) Agent: COHEN, Mark S. et al.; PEARL COHEN ZEDEK LATZER BARATZ LLP, 7 Times Square, 19th Floor, New York, New York 10036 (US).


(15) Information about Correction:

see Notice of 31 August 2023 (31.08.2023)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: BISPECIFIC ANTIBODIES TARGETING NKP46 AND CD38 AND METHODS OF USE THEREOF

FIG. 1A



(57) Abstract: This disclosure provides bispecific antibody molecules that specifically bind to NKp46 and CD38. The disclosure further relates to combination therapies comprising the bispecific antibody molecules. The bispecific antibody molecules can be used to treat, prevent and/or diagnose cancer or infectious conditions or disorders associated with cells expressing NKp46 and/or CD38.